Centralized monitoring for BE? [GxP / QC / QA]

posted by DavidManteigas – Portugal, 2017-07-14 20:24 (2449 d 11:55 ago) – Posting: # 17549
Views: 3,795

Hi all,

This is surely not my field of experience nor interest.

Nevertheless, I have been "colaborating" recently in centralized/risk-based monitoring for phase III trials, by providing the monitoring team with pre-defined reports for them to identify centers and forms to SDV. From my perspective, this approach will be more common and effective in the near future for this kind of trials. As regards to bioequivalence, I don't think this will be the case. I can't see how centralized monitoring can be used in this context. Only in the case of units that have eSource implemented and monitoring will be mostly performed on the data available on the eSource system. But in this case, what is the purpose of monitoring? Wouldn't the data management review and medical review "catch" every issue that a monitor could possibly identify?

Regards,
David

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
108 visitors (0 registered, 108 guests [including 10 identified bots]).
Forum time: 07:19 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5